Beta Bionics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Beta Bionics Inc (BBNX)
Beta Bionics Inc stock price live, this page displays NASDAQ BBNX stock exchange data. View the BBNX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Beta Bionics Inc real time stock price chart below.
What Is the Beta Bionics Inc Stock Price Today?
The Beta Bionics Inc stock price today is 16.40.
What Is the Stock Symbol for Beta Bionics Inc?
The stock symbol for Beta Bionics Inc is "BBNX."
What Stock Exchange Does Beta Bionics Inc Trade On?
Beta Bionics Inc is listed and trades on the NASDAQ stock exchange.
Is Beta Bionics Inc a Good Stock to Buy?
Determining whether Beta Bionics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBNX quote. (ISIN: US08659B1026)
What Is the Beta Bionics Inc Stock Price Today?
The Beta Bionics Inc stock price today is 16.40.
What Is the Stock Symbol for Beta Bionics Inc?
The stock symbol for Beta Bionics Inc is "BBNX."
What Stock Exchange Does Beta Bionics Inc Trade On?
Beta Bionics Inc is listed and trades on the NASDAQ stock exchange.
Is Beta Bionics Inc a Good Stock to Buy?
Determining whether Beta Bionics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBNX quote. (ISIN: US08659B1026)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.64
16.86
52 wk Range
8.80
32.71
BBNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.6416.86
52 wk Range
8.8032.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BBNX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
20.08
Upside
+22.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Beta Bionics Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Beta Bionics Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Beta Bionics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Beta Bionics Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
8 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 20.08
(+22.45% Upside)
Beta Bionics Inc Earnings Call Summary for Q2/2026
- Beta Bionics posted Q2 2026 revenue of $32M, up 38% YoY, but missed EPS estimates with a 53-cent loss vs. 34-cent forecast, a 55.9% miss.
- Gross margin improved to 59.0% from 53.76% YoY; company raised FY2026 margin guidance to 58.5%-59.5% and reaffirmed revenue outlook of $131M-$136M.
- Company ended quarter with $225M in cash; remains unprofitable with operating expenses rising 37% YoY to $44.5M amid sales and R&D expansion.
- Mint patch pump expected to launch by end of Q2 2027 pending FDA clearance; type 2 diabetes pivotal trial began July 2026 targeting mid-2027 indication.
- New patient starts rose 10-20% sequentially; over 30% came from type 2 diabetes patients, signaling expansion beyond core type 1 market.
Last Updated: 2026/07/29, 23:38
Read Full TranscriptEarnings
Latest Release
Jul 29, 2026
EPS / Forecast
-0,53 / -0,34
Revenue / Forecast
32M / --
Compare BBNX to Peers and Sector
Metrics to compare | BBNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.1x | −2.9x | −0.4x | |
PEG Ratio | −0.19 | −0.20 | 0.00 | |
Price/Book | 2.9x | 3.2x | 2.6x | |
Price / LTM Sales | 6.2x | 2.9x | 3.1x | |
Upside (Analyst Target) | 25.8% | 90.8% | 48.2% | |
Fair Value Upside | Unlock | −7.8% | 5.8% | Unlock |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Beta Bionics (BBNX) Stock Price Today?
The Beta Bionics stock price today is 16,40 USD.
What Stock Exchange Does Beta Bionics Trade On?
Beta Bionics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Beta Bionics?
The stock symbol for Beta Bionics is "BBNX."
What Is the Beta Bionics Market Cap?
As of today, Beta Bionics market cap is 737,83M USD.
What Is Beta Bionics's Earnings Per Share (TTM)?
The Beta Bionics EPS (TTM) is -1,65.
When Is the Next Beta Bionics Earnings Date?
Beta Bionics will release its next earnings report on Nov 03, 2026.
From a Technical Analysis Perspective, Is BBNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Beta Bionics Stock Split?
Beta Bionics has split 0 times.
How Many Employees Does Beta Bionics Have?
Beta Bionics has 422 employees.
What is the current trading status of Beta Bionics (BBNX)?
As of Aug 11, 2026, Beta Bionics (BBNX) is trading at a price of 16,40 USD, with a previous close of 15,90 USD. The stock has fluctuated within a day range of 15,64 USD to 16,86 USD, while its 52-week range spans from 8,80 USD to 32,71 USD.
What Is Beta Bionics (BBNX) Price Target According to Analysts?
The average 12-month price target for Beta Bionics is 20,08 USD, with a high estimate of 30.4 USD and a low estimate of 14 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +22,45% Upside potential.
What Is the BBNX Premarket Price?
BBNX's last pre-market stock price is 14,82 USD. The pre-market share volume is 1 140,00, and the stock has decreased by -1,08, or -6,79%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.